Mexico City Invests US$215 Million In Biotech Project
Mexico City government announced a health and research infrastructure project representing a total investment of more than US$214.9 million, aimed at creating the country’s first Interdisciplinary Center for Preventive Medicine in the Tlalpan municipality. The initiative will become the centerpiece of a new Innovation District designed to transform the southern part of the capital into a strategic hub for biotechnology and clinical research.
During the announcement at Tecnológico de Monterrey’s Tlalpan Campus, Mexico City Mayor Clara Brugada emphasized the structural shift the initiative aims to bring to the local economy.
“We want to move from an economy that produces services to one that also produces knowledge, from a city that buys technology to one that creates and develops it,” she said.
The initiative is expected to create more than 2,000 direct and indirect jobs for scientists, researchers, biotechnology specialists, and healthcare professionals.
The new complex will include facilities for scientific research, technological development, manufacturing, and health innovation. In addition to a clinical research center focused on the development of new drugs, it will feature areas dedicated to predictive medicine and precision oncology, with an emphasis on the early diagnosis of cancer and the comprehensive study of neurodegenerative and cardiometabolic diseases.
Regarding the project’s financing, Avant Santé announced its private investment commitment during the presentation. Sitaramaraju Yarramraju, the company’s founder and CEO, detailed an initial investment of US$15 million, which is expected to increase to US$125 million over a five-year period. This investment will be complemented by an additional US$100 million committed by three other companies interested in developing infrastructure in Mexico.
Operations at the facility are scheduled to begin in the second quarter of 2027, as Mexico City seeks to reduce its reliance on imported medical technology and establish itself as a national leader in biotechnology.
